Search OGEN
Oragenics, Inc.
NYSE American · CIK 1174940
Last close0.49
Daily change+0.01 (2.08%)
10 Years gain-99.99%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
OGEN · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
53.2Momentum
n/aAcceleration
n/aConfidence
73.0Annual Revenue11
Quarterly Revenue49
Annual CFO14
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality12.5 / 25
Capital Efficiency0.0 / 20
Balance Sheet13.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
High SBC · MEDIUMStock based compensation is high relative to revenue or FCF.
Key Metrics
Revenue Growth TTM63.05%OK
Revenue CAGR 3Yn/aINSUFFICIENT_HISTORY
Gross Margin100%OK
Operating Margin-9,713.09%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFO0.58xOK
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenue667.35%OK
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | n/a | $0.00 | -$9.36M | -$9.25M | n/a | n/a | n/a | n/a | n/a | 2.16M |
| 2025 FY Dec 31, 2024 | n/a | $0.00 | -$10.56M | -$8.60M | n/a | n/a | n/a | n/a | n/a | 220,731 |
| 2024 FY Dec 31, 2023 | $37,653.00 | $37,653.00 | -$20.90M | -$7.29M | n/a | 100% | -55,519.89% | n/a | -2,606.58% | 2.25M |
| 2023 FY Dec 31, 2022 | $131,521.00 | $131,521.00 | -$14.42M | -$15.23M | -$15.36M | 100% | -10,964.61% | -11,675.7% | -2,837.42% | 2.01M |
| 2022 FY Dec 31, 2021 | $86,987.00 | $86,987.00 | -$15.77M | -$13.47M | -$13.51M | 100% | -18,130.32% | -15,535.76% | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $123,700.00 | sum latest 4 fiscal quarters Revenue | OK | 0001493152-23-040060, 0001493152-24-019655 |
| Revenue Growth TTM | 63.05% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001493152-23-040060, 0001493152-24-019655 |
| Revenue CAGR 3Y | n/a | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001493152-25-010389 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001493152-25-010389 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001493152-25-010389 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001493152-23-040060, 0001493152-24-019655 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001493152-23-040060, 0001493152-24-019655 |
| Operating Margin | -9,713.09% | Operating Income / Revenue | OK | 0001493152-23-040060, 0001493152-24-019655 |
| Net Debt / CFO | 0.58x | Net Debt / CFO | OK | 0001493152-23-040060, 0001493152-23-027838 |
| Current Ratio | 5.57x | Current Assets / Current Liabilities | OK | derived |
| SBC / Revenue | 667.35% | SBC / Revenue | OK | 0001493152-23-040060, 0001493152-24-019655 |
| Revenue per Diluted Share | $0.05 | Revenue / Diluted Shares | OK | 0001493152-23-040060, 0001493152-24-019655 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | 0001493152-23-040060, 0001493152-24-019655 |